The average age for someone diagnosed with Kidney Cancer in the U.S. is 65. But one local man’s decades-long battle with ...

An artificial intelligence (AI)-based model developed by UT Southwestern Medical Center researchers can accurately predict ...

Although recommended, many patients with metastatic clear cell RCC still don’t receive immune checkpoint inhibitor-based combinations as first-line treatment.

A simple urine test could accurately show the recurrence of kidney cancer at an early stage, potentially sparing patients ...

During a live event, Guru P. Sonpavde, MD discussed improvements to survival with cabozantinib plus nivolumab in metastatic ...

Subcutaneous Opdivo showed comparable effectiveness, safety and tolerability to IV Opdivo in advanced clear cell renal cell ...

Over the past 5 years, targeted therapy has significantly impacted on metastatic renal cell carcinoma (mRCC ... At present, there is no clear evidence of superiority of either sequence (TKI ...

Published in Cell, this study showed that when the tumor suppressor gene VHL is inactivated by a mutation—a hallmark of clear ...

During a live event, Martin Voss, MD, reviewed the trials of lenvatinib plus pembrolizumab, cabozantinib plus nivolumab, and ...

The first-in-human PET imaging trial of 64 Cu-PD-32766 for patients with clear cell renal cell carcinoma (ccRCC) was conducted at the National Cancer Center Hospital East and promising results ...